Raben David 4
4 · Bicara Therapeutics Inc. · Filed Oct 10, 2025
Insider Transaction Report
Form 4
Raben David
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2025-10-09$3.79/sh+22,000$83,376→ 57,497 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-10-09−22,000→ 128,870 totalExercise: $3.79Exp: 2033-08-08→ Common Stock (22,000 underlying) - Sale
Common Stock
2025-10-09$18.45/sh−22,000$405,900→ 35,497 total
Footnotes (2)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
- [F2]25% of the shares underlying this option vested on July 24, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.